护肝片提高肝移植受者他克莫司血药浓度临床观察

目的：评价应用护肝片提高肝移植受者全血他克莫司（FK506）药物浓度的疗效。方法：将56例肝移植术后长期服用FK506的受者作为研究对象,FK506和护肝片同时服用的受者为试验组（27例）,单纯口服FK506的受者为对照组（29例）;检测两组全血FK506浓度及肝、肾功能,作为临床评价指标。结果：试验组服药后FK506血药浓度比服药前分别增加了2.718±0.45ng·mL^-1,增幅达60.35%,两者比较有显著性差异（P〈0.01）;与对照组比较亦有显著性差异（P〈0.01）。停用护肝片后,全血FK506浓度明显降低,降幅达32.30%,差异有显著性（P〈0.01）。FK506和护肝片合用对肝、肾功能指标无明显不良影响。结论：护肝片能明显提高他克莫司药物浓度。

Effect of Liver - aid Tablet on Bloods Concentration of Tacrolimus in Patients Undergoing Liver Transplantation

OBJECTIVE： To evaluate the efficacy of Liver-aid tablet in increasing tacrolimus （FK506）concentration in patients undergoing liver transplantation. METHODS： A total of 56 patients undergoing liver transplantation treated with FK506 were enrolled： 27 were assigned to receive FK506 plus Liver-aid tablet （experimental group）, and 29 to receive FK506 alone （control group）. Blood concentrations of FK506, and biochemistry indexes for liver and renal function were determined. RESULTS： After medication, the blood concentrations of FK506 in the experimental group increased 2.718 ±0.451ng·mL^-1（up 60.35 % ）, showing significant differences as compared with before medication （P 〈 0.01）, and the difference was also significant as compared with control group （ P 〈 0.01 ）. However, after withdrawal of the Liver - aid tablet, the blood concentrations of FK506 were significantly decreased, down 32.30 %, and the difference was significant （ P 〈 0.01）. Used in combination, FK506 and Liver - aid tablet had no significant effects on the indexes of liver or liver function. CONCLUSION： Liver- aid tablet could markedly elevate the blood concentration of FK506 in patients undergoing liver transplantation.